19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
Exelixis
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Exelixis
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Exelixis
Discovery and characterization of an inhibitor of glucosylceramide synthase.
Exelixis
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors.
Exelixis
The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Exelixis
Discovery of XL413, a potent and selective CDC7 inhibitor.
Exelixis
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Exelixis
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Exelixis
Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Exelixis
Discovery of a new class of glucosylceramide synthase inhibitors.
Exelixis
Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Exelixis
Cyanotriazole compounds
Otsuka Pharmaceutical
Substituted bicyclic compounds
Bristol-Myers Squibb
RIP1K inhibitors
Rigel Pharmaceuticals
Isoindolines as HDAC inhibitors
Valo Health
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
Bristol-Myers Squibb
Resorcinol derivatives as HSP90 inhibitors
Nerviano Medical Sciences
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
University of Padova